论文部分内容阅读
为开发一种具有调脂作用、有效防治冠心病的中药制剂 ,采用高胆固醇饲喂和大剂量垂体后叶素双重因素造成实验性冠心病大鼠模型 ,用沉淀酶联法和改良的双梯度聚丙烯酰胺凝胶电泳等技术 ,对大鼠的血脂、脂蛋白及其亚组分胆固醇、血清脂蛋白谱 (SLPG)进行了检测分析 ,并观察了由广州中医药大学第一附属医院研制的治疗冠心病、心绞痛及无症状心肌缺血的中药系列复方开心胶囊Ⅰ、Ⅱ号对其的影响。结果 :开心胶囊Ⅰ号 (生脉散加减 )具有降低总胆固醇 ( ρTC)、低密度脂蛋白胆固醇 ( ρLDL -c)作用 (P <0 .0 5 ) ;开心胶囊Ⅱ号 (越鞠丸合失笑散加减 )具有降低 ρTC、ρLDL -c和甘油三酯 ( ρTG)的作用 (P <0 .0 5 ,P <0 .0 1) ,并具有升高高密度脂蛋白胆固醇 ( ρHDL -c)作用。表明开心胶囊能够调整血脂水平 ,调整血清脂蛋白各亚组分平衡 ,降低动脉硬化指数 (KAI) ,因而具有抗动脉硬化的作用。
In order to develop a traditional Chinese medicine preparation with lipid regulating effect and effective prevention and treatment of coronary heart disease, an experimental coronary heart disease rat model was induced by high cholesterol feeding and large doses of pituitrin, using precipitated enzyme linkage and modified double gradients. Polyacrylamide gel electrophoresis and other techniques were used to detect and analyze serum lipids, lipoproteins and their sub-component cholesterol and serum lipoprotein profile (SLPG) in rats, and were observed by the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine. The effects of Chinese Herbal Compound Kaixin Capsules I and II on coronary heart disease, angina pectoris and asymptomatic myocardial ischemia were studied. RESULTS: Kaixin Capsule I (Shengmai Powder) had the effects of lowering total cholesterol (ρTC) and low-density lipoprotein cholesterol (ρLDL-c) (P <0.05); Kaixin Capsule II (Hsuanyu Pills and Laughing) Scattered additions and subtractions) had the effect of reducing ρTC, ρLDL-c and triglyceride (ρTG) (P <0.05, P <0.01), and having elevated HDL cholesterol (ρHDL-c). effect. It shows that Kaixin Capsule can adjust the blood lipid level, adjust the balance of serum lipoprotein subcomponents, and reduce the arteriosclerosis index (KAI), thus having anti-atherogenic effect.